Appendix cancer future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Appendix cancer}} {{CMG}}; {{Soroush}} ==Overview== ==Future Therapies== *Genetic studies revolutionized cancer treatment; appendix cancer is not an exception...." |
No edit summary |
||
| Line 16: | Line 16: | ||
** Patients with GNAS mutations had a life expectancy of 10 years after diagnosis. | ** Patients with GNAS mutations had a life expectancy of 10 years after diagnosis. | ||
** Appendiceal tumors with GNAS mutations rarely develop into high-grade tumors. | ** Appendiceal tumors with GNAS mutations rarely develop into high-grade tumors. | ||
==References== | |||
{{Reflist|2}} | |||
Revision as of 14:42, 22 February 2019
|
Appendix cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Appendix cancer future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Appendix cancer future or investigational therapies |
|
Appendix cancer future or investigational therapies in the news |
|
Blogs on Appendix cancer future or investigational therapies |
|
Risk calculators and risk factors for Appendix cancer future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Soroush Seifirad, M.D.[2]
Overview
Future Therapies
- Genetic studies revolutionized cancer treatment; appendix cancer is not an exception.
- Traditionally appendiceal cancers were approached the same as colorectal cancers. Recent genetic studies demonstrated that appendiceal tumors are clearly differ from colorectal cancers.[1]
- Presence of mutated TP53 and APC genes were significantly lower in appendiceal cancers compared to colorectal cancers.
- It has been shown that mutation profiles are associated with the patients’ prognosis. [2]
- Mutations in the TP53 significantly decrease life expectancy in patients with appendix cancer.
- Regardless of tumor grade, Tp 53 mutations were associated with poorer outcomes.
- Patients with GNAS mutations had a life expectancy of 10 years after diagnosis.
- Appendiceal tumors with GNAS mutations rarely develop into high-grade tumors.
References
- ↑ Levine EA, Blazer DG, Kim MK, Shen P, Stewart JH, Guy C; et al. (2012). "Gene expression profiling of peritoneal metastases from appendiceal and colon cancer demonstrates unique biologic signatures and predicts patient outcomes". J Am Coll Surg. 214 (4): 599–606, discussion 606-7. doi:10.1016/j.jamcollsurg.2011.12.028. PMC 3768122. PMID 22342786.
- ↑ Levine EA, Votanopoulos KI, Qasem SA, Philip J, Cummins KA, Chou JW; et al. (2016). "Prognostic Molecular Subtypes of Low-Grade Cancer of the Appendix". J Am Coll Surg. 222 (4): 493–503. doi:10.1016/j.jamcollsurg.2015.12.012. PMC 4808611. PMID 26821970.